ClinicalTrials.gg
TerminatedNCT05207709HARMONIAUpdated Jun 25, 2026

Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype

A Phase 3 interventional study of Ribociclib + Letrozole OR Fulvestrant and Palbociclib + Letrozole OR Fulvestrant in Metastatic Breast Cancer, sponsored by SOLTI Breast Cancer Research Group. Terminated at 71 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by SOLTI Breast Cancer Research Group · Phase 3, Interventional, and Treatment

How we know · 6 judgments

Why this study was terminated
The study was prematurely halted because enrollment was significantly delayed compared with the original projections due to the evolving therapeutic landscape.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 373 studies testing paclitaxel in Breast Neoplasms — 40 open to participants now, 60 under way, 13 of them phase 3. Paclitaxel · Breast Neoplasms.

Enrollment
180th of 361
61 · median 60
Started
2022
with 13 others
Phase 3
61 of 373
6 open now
Registered
336th of 373
by date

Among the 373 studies testing paclitaxel in Breast Neoplasms, this one is the 180th largest by enrollment of the 361 interventional ones that give a count, is one of 14 that started in 2022, is one of 61 in phase 3, and was the 336th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

40 of the 373 studies testing paclitaxel in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

35 more — sign in →

By country, each count listing its studies:

All 40 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 373 studies testing paclitaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

HARMONIA is an international, multicenter, randomized, open-label and phase III study. The primary objective of this study is to demonstrate that the combination of ribociclib with endocrine therapy (letrozole or fulvestrant) is superior to palbociclib with endocrine therapy (letrozole or fulvestrant) in prolonging progression-free survival in patients with advanced HR+/HER2- and HER2-E breast cancer. The study will enroll approximately 456 patients with HER2-E disease from approximately 95 sites worldwide.

In addition, the HARMONIA trial will include an exploratory cohort of patients with HR+/HER2- and Basal-like disease treated with paclitaxel +/- Tislelizumab. This cohort does not have a predefined sample size and the objective is only exploratory, given the suggested lack of efficacy of the combinations of hormone therapy and CDK4/6 inhibitors in this subgroup of patients. Enrolment into the basal-like cohort will stop once the HER2-E disease cohort is fully enrolled.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

Keywords

  • PAM50
  • intrinsic subtype
  • HER2-Enriched
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • documented HR-positive and -negative breast cancer by local testing
  • (ECOG) performance status of 0 to 1.
  • advanced (loco regionally recurrent not amenable to curative therapy or ) breast cancer.
  • Availability of FFPE tumor block for biomarker analysis, obtained during metastatic period.
  • HER2-E or Basal-like subtype as per central PAM50 analysis.
  • or non-measurable disease, as defined by v1.1
  • Adequate hematologic and end-organ function
  • Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures.
  • Women of must have confirmed negative serum pregnancy test within 7 days prior to randomization.
  • Women of CBP must be willing to use highly effective methods of .
  • Patient must have a 6-lead or 12-lead with ALL of the following parameters at screening:

    • interval (QT interval using Fridericia's correction) at screening \< 450 msec.
    • Resting heart rate 50-90 beats per minute (determined from the ECG).

Main Exclusion Criteria:

  • Prior therapy with any CDK4/6 inhibitors.
  • Patient has received prior treatment with chemotherapy for advanced/metastatic breast cancer
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Ribociclib + Endocrine Therapy

    Ribociclib + Fulvestrant or Letrozole

    Drug: Ribociclib + Letrozole OR Fulvestrant

  • Experimental
    Palbociclib + Endocrine Therapy

    Palbociclib + Fulvestrant or Letrozole

    Drug: Palbociclib + Letrozole OR Fulvestrant

  • Experimental
    Paclitaxel +/- Tislelizumab - Exploratory cohort

    Additional experimental Cohort that includes patients with Basal-Like intrinsic subtype.

    Drug: Paclitaxel +/- Tislelizumab

Interventions

  • DrugRibociclib + Letrozole OR Fulvestrant

    Endocrine Therapy will be selected by the investigator. For premenopausal women and men: LHRH agonist once every 4 weeks

  • DrugPalbociclib + Letrozole OR Fulvestrant

    Endocrine Therapy will be selected by the investigator. For premenopausal women and men: LHRH agonist once every 4 weeks

  • DrugPaclitaxel +/- Tislelizumab

    Drug pages: PaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TislelizumabStudies of TislelizumabTislelizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients in this arm could receive as the first line of therapy

This study also gives PalbociclibStudies of PalbociclibPalbociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., RibociclibStudies of RibociclibRibociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., FulvestrantStudies of FulvestrantFulvestrant pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression-free survival

    using RECIST 1.1 criteria, as assessed by local radiologists/investigators

    Time frame: From date of randomization until the date of first documented progression, death, lost of follow-up, withdraw consent or the study is terminated by SOLTI, whichever occurs first, assessed up to approximately 62 months after the first patient enrolled

Secondary outcomes

  1. Progression-free survival 2

    defined as the time from randomization to first documented progression on next-line therapy or death, whichever occurs first

    Time frame: From randomization until documented progression to second line of therapy, death, lost of follow-up, withdraw consent or the study is terminated by SOLTI, whichever occurs first, assessed up to approximately 62 months after the first patient enrolled

  2. Overall Survival

    the proportion of exitus patients

    Time frame: until patient death, assessed up to approximately 62 months after the first patient enrolled

  3. Overall response and clinical benefit

    defined as percentage of patients with CR, PR per RECIST 1.1 or SD lasting 24 weeks or longer, as defined by RECIST 1.1.

    Time frame: until disease progression or 24 weeks from treatment start.

  4. Time to response and duration of response

    defined per RECIST 1.1

    Time frame: time from treatment start to response and time from response to disease progression, assessed up to approximately 62 months after the first patient enrolled

  5. Adverse events (safety)

    Occurrence /severity of AEs, laboratory abnormalities, discontinuation rates, dose reductions/interruptions

    Time frame: from randomization/enrollment to end of study assessed up to approximately 62 months after the first patient enrolled

07

Study locations

71 sites
  • Morton Plant Hospital
    Clearwater, Florida 33756, United States
  • University of Miami
    Coral Gables, Florida 33124, United States
  • Memorial Regional Hospital
    Hollywood, Florida 33021, United States
  • Mount Sinai Florida
    Miami, Florida 33140, United States
  • Northwestern
    Chicago, Illinois 60611, United States
  • Carle Cancer Center
    Urbana, Illinois 61801, United States
  • University of Kentucky, Markey Cancer Center
    Lexington, Kentucky 40536, United States
  • Sinai of Baltimore
    Baltimore, Maryland 21215, United States
  • Dana Faber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Baptist Memorial Health Care
    Oxford, Mississippi 38655, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Nevada Cancer Research Foundation
    Las Vegas, Nevada 89121, United States
  • NHOH
    Londonderry, New Hampshire 03053, United States
  • Nothwell Health
    New York, New York 11042-1069, United States
  • Montefiore
    The Bronx, New York 10467, United States
  • University of North Carolina Lineberger
    Chapel Hill, North Carolina 27514, United States
  • Novant Health Care
    Winston-Salem, North Carolina 27103, United States
  • Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • Dayton Clinical Oncology
    Kettering, Ohio 45429, United States
  • Legacy Good Samaritan Hospital and Medical Cente
    Portland, Oregon 97210, United States
  • Providence Portland Medical Center
    Portland, Oregon 97225, United States
  • The Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Upstate Carolina Medical Center
    Spartanburg, South Carolina 29302, United States
  • Edwards Comprehensive Cancer Center
    Huntington, Virginia 25701, United States
  • Bon Secours Memorial Regional Medical Center
    Mechanicsville, Virginia 231136, United States
  • Unv. Wisconsin
    Madison, Wisconsin 53792, United States
  • Hospital Senhora da Oliveira - Guimarães
    Creixomil, Portugal
  • IPO Lisboa
    Lisbon, 1500-650, Portugal
  • Hospital Beatriz Ângelo
    Loures, 2674-514, Portugal
  • Instituto Portugues de Oncologia de Porto Francisco Gentil, EPE
    Porto, 4200-072, Portugal
  • Centro Hospitalar Vila Nova de Gaia
    Vila Nova de Gaia, 4434-502, Portugal
  • Hospital Son Llàtzer
    Palma de Mallorca, Balearic Islands 07198, Spain
  • Institut Català d' Oncologia (ICO Badalona)
    Badalona, Barcelona 08916, Spain
  • Hospital del Mar
    Barcelona, Barcelona 08003, Spain
  • IOB-Institute of Oncology. Hospital Quironsalud Barcelona
    Barcelona, Barcelona 8023, Spain
  • Institut Català d'Oncologia (ICO Hospitalet)
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
  • Hospital General de Catalunya
    Sant Cugat del Vallès, Barcelona 08195, Spain
  • Hospital Universitario de Canarias
    Santa Cruz de Tenerife, Canary Islands 38320, Spain
  • Institut Català d' Oncologia de Girona (ICO Girona)
    Girona, Girona 17007, Spain
  • Hospital Clínico Universitario de A Coruña
    A Coruña, La Coruña 15006, Spain
  • Hospital Clínico Universitario de Santiago CHUS
    Santiago de Compostela, La Coruña 15706, Spain
  • Complejo Asistencial Universitario de León
    León, León 24001, Spain
  • Hospital Universitario de Fuenlabrada
    Fuenlabrada, Madrid 28942, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, Madrid 28034, Spain
  • Fundación Jiménez Díaz
    Madrid, Madrid 28040, Spain
  • Hospital La Paz
    Madrid, Madrid 28046, Spain
  • Hospital Universitario Virgen de la Arrixaca
    El Palmar, Murcia 30120, Spain
  • Hospital Universitario Morales Meseguer
    Murcia, Murcia 30008, Spain
  • Hospital Quiron Salud Sagrado Corazon Sevilla
    Seville, Sevilla 41013, Spain
  • Hospital Universitario Virgen del Rocio
    Seville, Sevilla 41013, Spain
  • Hospital Clínico Universitario Lozano Blesa
    Zaragoza, Zaragoza 50009, Spain
  • Hospital General Universitario de Alicante
    Alicante, 03010, Spain
  • Vall d´Hebron University Hospital
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital de Basurto
    Bilbao, 48013, Spain
  • Complejo Hospitalario San Pedro de Alcántara
    Cáceres, 10003, Spain
  • Hospital Universitario Virgen de las Nieves
    Granada, 18014, Spain
  • H. Clínico San Cecilio de Granada
    Granada, 18016, Spain
  • Hospital Universitario de Gran Canaria Doctor Negrin
    Las Palmas, 35010, Spain
  • Hospital Universitari Arnau de Vilanova de Lleida
    Lleida, 25198, Spain
  • Hospital Universitario La Princesa
    Madrid, 28006, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Centro Integral Oncológico Clara Campal (CIOCC)
    Madrid, 28050, Spain
  • Hospital Universitario Puerta de Hierro de Majadahonda
    Madrid, 28222, Spain
  • Hospital Virgen de la Victoria
    Málaga, 29010, Spain
  • Hospital Sant Joan de Reus
    Reus, 43204, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Universitario Marqués de Valdecilla
    Santander, 39008, Spain
  • Hospital Virgen de la Macarena
    Seville, 41007, Spain
  • Instituto Valenciano de Oncología (IVO)
    Valencia, 46009, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
08

References and documents

Publications

  • Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C, Ahn H, Trivedi MS, Novik Y, Tiersten A, Raptis G, Baer LN, Oh SY, Zelnak AB, Wisinski KB, Andreopoulou E, Gradishar WJ, Stringer-Reasor E, Reid SA, O'Dea A, O'Regan R, Crew KD, Hershman DL. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. J Clin Oncol. 2023 Aug 20;41(24):4004-4013. doi: 10.1200/JCO.22.02392. Epub 2023 May 19. PubMed 37207300 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Mar 2026, 47 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2022
First posted
Jan 26, 2022
StartActual
Mar 28, 2022
Primary completionActual
Mar 26, 2026
CompletionActual
Mar 26, 2026
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05207709
Lead sponsor
SOLTI Breast Cancer Research Group
Collaborators
Novartis, Alliance Foundation Trials, LLC.
Responsible party
Sponsor
First posted
Jan 26, 2022
Start date
Mar 28, 2022
Primary completion
Mar 26, 2026
Completion
Mar 26, 2026
Last update
Jun 25, 2026

Study contacts

Aleix Prat, MD
principal investigator · Hospital Clínic of Barcelona / SOLTI
Lisa A Carey, MD
principal investigator · UNC Lineberger Comprehensive Cancer Center
Dan G Stover, MD
principal investigator · Stefanie Spielman Comprehensive Breast Center
Tomás Pascual, MD
principal investigator · Hospital Clínic of Barcelona / SOLTI cancer research group

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paclitaxel · Tislelizumab · Ribociclib

Start the discussion